EncephalX closes $1M seed round — Sherbrooke Innopole
Summary
PRESS RELEASE EncephalX, a bioengineering start-up led by Simon Lapointe (CEO), proudly announces the closing of its first financing round representing $1M.EncephalX works in the field of neurosurgical devices, mainly focusing on the commercialization of a cranial fixation plate that is installed directly with the patients bone flap when a decompressive craniectomy is required, an essential surgery for the treatment of severe head trauma. This investment will be used to complete the pre-clinical stage and to obtain the regulatory approval for its clinical trials.This first financing round was co-led by ACET Capital and Sherbrooke Innopole, but also supported by several other partners such as Front Row Venture and neurosurgeons. Dominic Denis, Investment Director at ACET CapitalSherbrooke Innopole is pleased to support EncephalX, a high-potential young company in the Life Sciences sector, in the development of its dynamic cranioplasty system for the treatment of intracranial hypertension. Emmanuelle Coppinger, Managing Partner at Front Row VenturesACETs mission is to identify innovative and ambitious technological projects, to support entrepreneurs in their development and to propel promising new companies with a positive societal impact. Its mission is to accelerate the development of companies from the five key sectors Advanced Manufacturing, Quantum and Information Technologies, Cleantech, Life Sciences and Micro- Nanotechnologies and ensure that Sherbrooke has an attractive and innovative business environment.